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Antibacterial activityAbstract Anti-inﬂammatory and antibacterial activities of some novel quinazolinones were deter-
mined. Evaluation of anti-inﬂammatory activity of test compounds was performed using carra-
geenan induced paw edema in rats. Oral administration of test compounds 25 mg/kg and 50 mg/
kg reduced the paw edema signiﬁcantly (P< 0.05) in a dose dependent manner compared to car-
rageenan induced rats. The test compounds were also screened for their antibacterial activity
against the strains of Staphylococcus aureus and Escherichia coli at the concentrations of 200 lg/
ml and 1 mg/ml. The test compounds showed better activity as that of the standard lincomycin
at the tested higher concentration against S. aureus. None of the compounds exhibit comparable
activity to that of the standard ceftazidime against E. coli.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
In general, the quinazolones are considered to be important
compounds in the ﬁelds of pharmacy and biology. Microbial
infections often produce pain and inﬂammation. The com-
pounds possessing anti-inﬂammatory activity with antibacterial
activities are not known. Quinazolinone derivatives exhibit awide range of biological activities like analgesic, anti-inﬂamma-
tory, antibacterial (Alagarsamy et al., 2003), antifungal (Anshu
et al., 2005), antiviral (Dinakaran et al., 2003), antihistaminic
(Lemura et al., 1989), antihypertensive (Samir et al., 1989), anti-
cancer (Anjani et al., 2006), antihyperglycemic (Vishnu et al.,
2003) and anti-HIV (Alagarsamy et al., 2003). The tested com-
pounds (See Fig. 1) were synthesised by our earlier reported
method (Muthumani et al., 2010). The compounds were tested
for antibacterial and anti-inﬂammatory activities.
2. Materials and methods
2.1. Drugs and chemicals
Carrageenan, carboxy methyl cellulose (CMC) and dimethyl
formamide (DMF) were obtained from Merck, Mumbai.
Table 1 Percentage inhibition of test compounds (25 mg/kg) against carrageenan-induced paw edema in rats.
S. No. Drug 25 mg/kg Normal paw volume Drug administration Percentage inhibition
0.5 h 1 h 2 h 3 h
1 Control 0.49 ± 0.01 0.74 ± 0.08 0.75 ± 0.05 0.74 ± 0.04 0.72 ± 0.01 –
2 PBV-1 0.46 ± 0.03 0.71 ± 0.01 0.67 ± 0.05 0.65 ± 0.02 0.63 ± 0.02* 50
3 PBV-2 0.48 ± 0.05 0.74 ± 0.05 0.70 ± 0.03 0.68 ± 0.01 0.65 ± 0.01* 38
4 PBV-3 0.46 ± 0.01 0.71 ± 0.01 0.68 ± 0.05 0.68 ± 0.02 0.66 ± 0.005* 33
5 PBV-4 0.50 ± 0.02 0.75 ± 0.03 0.70 ± 0.02 0.65 ± 0.02 0.64 ± 0.02* 44
6 PBV-5 0.47 ± 0.01 0.73 ± 0.05 0.70 ± 0.05 0.67 ± 0.01 0.66 ± 0.01* 33
7 Standard 0.49 ± 0.05 0.75 ± 0.02 0.69 ± 0.01 0.62 ± 0.05 0.54 ± 0.02* 100
* P< 0.05 against control at the third hour. Values are expressed as mean ± SEM, n= 6 rats in each group. The statistical analysis was
performed by using Graph pad prism software version 4.03. The level of signiﬁcance was calculated by One way analysis of variance followed by
Dunnet’s multiple comparison test.
Table 2 Percentage inhibition of test compounds (50 mg/kg) against carrageenan-induced paw edema in rats.
S. No. Drug 50 mg/kg Normal paw volume Drug administration Percentage inhibition
0.5 h 1 h 2 h 3 h
1 Control 0.48 ± 0.01 0.75 ± 0.02 0.76 ± 0.02 0.76 ± 0.01 0.74 ± 0.002 –
2 PBV-1 0.50 ± 0.03 0.76 ± 0.03 0.70 ± 0.01 0.63 ± 0.05 0.59 ± 0.05* 60
3 PBV-2 0.48 ± 0.02 0.74 ± 0.05 0.63 ± 0.05 0.60 ± 0.02* 0.62 ± 0.03* 48
4 PBV-3 0.46 ± 0.05 0.72 ± 0.01 0.68 ± 0.05 0.68 ± 0.03 0.64 ± 0.02* 40
5 PBV-4 0.49 ± 0.08 0.74 ± 0.01 0.71 ± 0.01 0.64 ± 0.05 0.60 ± 0.04* 56
6 PBV-5 0.47 ± 0.05 0.73 ± 0.05 0.69 ± 0.04 0.69 ± 0.01* 0.63 ± 0.01* 44
7 Standard 0.46 ± 0.02 0.73 ± 0.02 0.66 ± 0.03 0.56 ± 0.05* 0.49 ± 0.01* 100
* P< 0.05 against control at the third hour. Values are expressed as mean ± SEM, n= 6 rats in each group. The statistical analysis was
performed by using Graph pad prism software version 4.03. The level of signiﬁcance was calculated by One way analysis of variance followed by
Dunnet’s multiple comparison test.
1050 R. Nanthakumar et al.Lincomycin and ceftazidime were obtained from Hi-media
labs, Mumbai. The standard drug, Valdecoxib was obtained
from Lyka hetero healthcare limited, Mumbai.
2.2. Animals
Female Sprague-Dawley rats (150–200 g) were obtained and
maintained in the Central Animal house. Animals were housed
in polypropylene cages at a room temperature of 21 ± 2 C
with 12 h of light and dark cycles and had free access to water
ad libitum. Animal experimental protocols have been approved
by an institutional animal ethics committee. Antibacterial
activity was performed at Vijay labs, Madurai according to
the protocol mentioned.
2.3. Anti-inﬂammatory activity of some novel quinazolinones
against carrageenan-induced paw edema in rats
Anti-inﬂammatory activity wasmeasured using carrageenan-in-
duced paw edema in rats (Winter et al., 1962). Rats were divided
into different groups each consisting of six animals and given
oral administration of 1%CMC (untreated control), valdecoxib
(reference control), and test compounds PBV-1 to PBV-5 were
administered at a dose of 25 mg/kg, 50 mg/kg. Thirty minutes
later, the rats were challenged by a subcutaneous injection of
0.05 ml of 1% w/v solution of carrageenan into the plantar side
of the left hind paw. The paw volume was measured using the
mercury displacement technique with the help of plethysmome-
ter (Ugo Basile, Italy). Paw volume of the untreated control, ref-erence control and test compoundswasmeasured at 0.5, 1, 2 and
3 h after carrageenan treatment. The difference between mean
paw volume of control and standard is considered as 100%
and the difference between the mean paw volume of control
and test compounds treated groupswas expressedwith reference
to the standard and percentage inhibition was calculated and
tabulated (Tables 1 and 2).
2.4. Antibacterial activity of some novel quinazolinones (Mackie
et al., 1978)
Staphylococcus aureus (MTCC 96) and Escherichia coli
(MTCC 722) were used for this study. Mueller-Hinton agar
media of 100 ml was prepared as per the composition and ster-
ilized in an autoclave at 15 lbs/in2 for 20 min. When the med-
ium was in a warm molten state, 100 ll of over night incubated
test culture was seeded. From this, 27 ml was transferred into
sterile petri plates and allowed to solidify. Solutions of stan-
dard (lincomycin and ceftazidime) and sample (PBV-1 to
PBV-8) were prepared (200 lg/ml and 1 mg/ml) using DMF
as a solvent in sterile cotton plugged tubes. The ﬁlter paper
discs of 5 mm diameter were soaked in standard, test solutions
and solvent control DMF. After evaporating the solvent in a
sterile atmosphere, the drug impregnated discs were placed
over seeded agar medium in petri plates. The plates were refrig-
erated for 1 h to arrest the growth and for easier diffusion of
test compounds. Then the plates were removed from the refrig-
erator and incubated at 37 C over night in an inverted condi-
tion and the zone of inhibition was measured and tabulated
(Table 3).
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Figure 1 Structures of title compounds.
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Figure 2 Percentage inhibition of test compounds against
carrageenan-induced paw edema in rats.
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Figure 3 Antibacterial activity of test compounds against S.
aureus.
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3.1. Anti-inﬂammatory activity
The role of test compounds (PBV-1 to PBV-5) on carrageenan-
induced acute inﬂammation model was evaluated at concentra-
tions of 25 mg/kg and 50 mg/kg. Edema was reduced by test
compounds in a dose dependent manner till the end of the
third hour. In carrageenan administered animals the severe
swelling was reached at 1 h and the swelling was maintained
until the third hour. The valdecoxib treated groups decreased
paw edema signiﬁcantly throughout the period of study. The
swelling was completely reduced during the third hour in val-decoxib treated rats. However, the animals treated with test
compounds (50 mg/kg) showed considerable inhibition on
swelling as compared to carrageenan administered animals.
Similarly the animals treated with test compounds (25 mg/
kg) also showed moderate inhibition on swelling as compared
to carrageenan induced animals. The results revealed that all
the test compounds protected the rats from carrageenan
induced inﬂammation and the test compounds showed a
signiﬁcant anti-inﬂammatory activity against the control group
(see Fig. 2). All the compounds signiﬁcantly reduced the
inﬂammation after the third hour. Among the compounds
tested PBV-1 and PBV-4 showed better anti-inﬂammatory
activity. PBV-2, PBV-3 and PBV-5 showed moderate activity
at both the doses tested.
Carrageenan-induced paw edema as an in vivo model of
inﬂammation has been frequently used to assess the anti-edem-
atous effects, which is known to be sensitive to cycloxygenase
(COX) inhibitors and has been used to evaluate the effects of
NSAID. Development of edema in the paw of the rat after
the injection of carrageenan involves three phases by several
inﬂammatory mediators released in an ordinary sequence.
An initial phase during the ﬁrst 1.5 h is caused by the release
of histamine and serotonin, the second phase is mediated by
bradykinin-like substances from 1.5 to 2.5 h. The treatment
with the COX-1 inhibitor could reduce the ﬁrst and second
phases of paw edema (Siqueira-Junior et al., 2003). Finally,
COX-2 is up-regulated only in the third phase, the mediator
of which is suspected to be prostaglandins, proteases and
lysosymes occur from 2.5 to 6 h after carrageenan injection
(Guang-Ming et al., 2010). The results of our in vivo study (Ta-
bles 1 and 2) indicated that the test compounds were able to
effectively inhibit edema in the third phase, suggesting that test
compounds inhibited cyclo oxygenase pathway of
inﬂammation.
3.2. Antibacterial activity
The results of the antibacterial screening of the test com-
pounds are presented (see Figs. 3 and 4). Antibacterial activity
of the test compounds in DMF was determined by Filter paper
disc method at concentrations of 200 lg/ml and 1 mg/ml. All
05
10
15
20
25
30
PBV-1 PBV-2 PBV-3 PBV-4 PBV-5 PBV-6 PBV-7 PBV-8 Standard
Test Compounds
Zo
ne
 o
f I
nh
ib
iti
on
 (m
m)
200 mcg/ml 1 mg/ml
Figure 4 Anti-bacterial activity of test compounds against
E. coli.
Figure 5 Antibacterial activity against S. aureus (200 lg/ml).
The zone of inhibition in mm for the test compounds PBV-1 to
PBV-4 at the concentration 200 lg/ml against S. aureus was found
to be 14, 13, 14 and 15, respectively.
Figure 6 Antibacterial activity against S. aureus (200 lg/ml).
The zone of inhibition in mm for the test compounds PBV-5 to
PBV-8 at the concentration 200 lg/ml against S. aureus was found
to be 12, 13, 14 and 12, respectively.
Figure 7 Antibacterial activity against S. aureus (1 mg/ml). The
zone of inhibition in mm for the test compounds PBV-1 to PBV-4
at the concentration 1 mg/ml against S. aureus was found to be 18,
16, 18 and 22, respectively.
Figure 8 Antibacterial activity against S. aureus (1 mg/ml). The
zone of inhibition in mm for the test compounds PBV-5 to PBV-8
at the concentration 1 mg/ml against S. aureus was found to be 18,
19, 24 and 19, respectively.
Figure 9 Antibacterial activity against E. coli (200 lg/ml). The
zone of inhibition in mm for the test compounds PBV-1 to PBV-4
at the concentration 200 lg/ml against E. coli was found to be 7, 8,
7 and 6, respectively.
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Figure 10 Antibacterial activity against E. coli (200 lg/ml). The
zone of inhibition in mm for the test compounds PBV-5 to PBV-8
at the concentration 200 lg/ml against E. coli was found to be 10,
8, 10 and 7, respectively.
Figure 11 Antibacterial activity against E. coli (1 mg/ml). The
zone of inhibition in mm for the test compounds PBV-1 to PBV-4
at the concentration 1 mg/ml against E. coli was found to be 12,
15, 14 and 11, respectively.
Figure 12 Antibacterial activity against E. coli (1 mg/ml). The
zone of inhibition in mm for the test compounds PBV-5 to PBV-8
at the concentration 1 mg/ml against E. coli was found to be 16,
15, 13 and 11, respectively.
Table 3 Antibacterial activity of test compounds against
S. aureus and E. coli.
Test
compounds
Zone of inhibition
in mm against S. aureus
Zone of inhibition in
mm against E. coli
200 lg/ml 1 mg/ml 200 lg/ml 1 mg/ml
PBV-1 14 18 7 12
PBV-2 13 16 8 15
PBV-3 14 18 7 14
PBV-4 15 22 6 11
PBV-5 12 18 10 16
PBV-6 13 19 8 15
PBV-7 14 24 10 13
PBV-8 12 19 7 11
Standard 18 24 17 27
Anti-inﬂammatory and antibacterial activity studyof some novel quinazolinones 1053the compounds showed comparable activity as that of the stan-
dard lincomycin against S. aureus (MTCC 96) (see Figs. 5–8).
None of the test compounds could exhibit comparable activity
to that of the standard ceftazidime against E. coli (MTCC 722)
(see Figs. 9–12). The test compounds showed a better activity
at the tested higher concentration (1 mg/ml) than at the lower
concentration (200 lg/ml) against S. aureus. The compounds
PBV-4 and PBV-7 are promising ones against S. aureus.4. Conclusion
The present study results showed the antibacterial and anti-
inﬂammatory activities of the test compounds. As NSAIDs
are associated with the side effect of ulcer, the test compounds
can be evaluated for their ulcer potential. In antibacterial
activity a further test can be done using a higher concentration
of more than 1 mg/ml if diffusion is not the barrier. In future,
some more test organisms of gram positive and gram negative
types can be used. In conclusion we suggest that the future
studies on these quinazolones could be useful for the manage-
ment of bacterial infections and inﬂammatory diseases.Acknowledgement
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